CompletedNCT01570959
Quetiapine 300 mg: Bioequivalence at Steady State Without Food
About this title
Read the official source — NCT01570959Medication studyAges 18–55United StatesBipolarity
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Garden Grove and 6 more locationsSee all locations and recruitment
Study information
Study start dateApril 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 56
- Sponsor
- Roxane Laboratories
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT01570959
- Official title
Show the full official title
A Two Period, Two Treatment, Two Way, Steady State Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Fasting Conditions
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Garden Grove · National City · North Miami
4 more locations
- Princeton
- Willingboro
- Austin
- Houston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Roxane Laboratories, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine Fumarate.
Who was this study for?
Listed age limits: 18 years to 55 years.
